Amedisys (AMED) Tops Q3 EPS by $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Amedisys Reports Third Quarter 2021 Financial Results Updates 2021 Guidance
November 2, 2021 4:05 PM EDTBATON ROUGE, La., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2021.
Three-Month Periods Ended September 30, 2021 and 2020
Net service revenue increased $9.4Â million to $553.5Â million compared to $544.1Â million in 2020.Net income attributable to Amedisys, Inc. of $45.0Â million compared to $72.0Â million (inclusive of a $24.0Â million income tax benefit related to executive stock option exercise) in 2020.Net income attributable to Amedisys, Inc. per diluted share of $1.37 compared to $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) in 2020.Adjusted... More
